Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
REOLYSIN
ONCOLYTICS BIOTECH INC
Carcinoma, Squamous Cell of the Head and Neck
2 trials -
Bevacizumab
ONCOLYTICS BIOTECH INC
Ras-mutated Metastatic Colorectal Cancer
1 trial -
Docetaxel, Reolysin and Prednisone
ONCOLYTICS BIOTECH INC
Prostate Cancer
1 trial -
Folfox plus Bevacizumab and reolysin
ONCOLYTICS BIOTECH INC
Colorectal Cancer
1 trial -
Paclitaxel
ONCOLYTICS BIOTECH INC
Metastatic Breast Cancer
1 trial -
Paclitaxel
ONCOLYTICS BIOTECH INC
Breast Cancer Metastatic
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Anal Cancer Metastatic
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Anatomic Stage IV Breast Cancer AJCC v8
1 trial -
Pemetrexed and Reolysin (and safety run-in)
ONCOLYTICS BIOTECH INC
Non Small Cell Lung Cancer
1 trial -
REOLYSIN
ONCOLYTICS BIOTECH INC
Metastatic Melanoma
1 trial -
REOLYSIN
ONCOLYTICS BIOTECH INC
Metastatic Pancreatic Adenocarcinoma
1 trial -
REOLYSIN
ONCOLYTICS BIOTECH INC
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Carcinoma, Non-small Cell Lung
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Osteosarcoma
1 trial -
pelareorep, Tecentriq 840 mg concentrate for solution for infusion
ONCOLYTICS BIOTECH INC
Patients with advanced or metastatic gastrointestinal (GI) tumors.
1 trial -
Bortezomib
ONCOLYTICS BIOTECH INC
Recurrent Plasma Cell Myeloma
1 trial -
Carfilzomib
ONCOLYTICS BIOTECH INC
Recurrent Plasma Cell Myeloma
1 trial -
Lenalidomide or Pomalidomide
ONCOLYTICS BIOTECH INC
Multiple Myeloma
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Breast Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Malignant Glioma
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Muscle-invasive Transitional Cell Carcinoma of the Bladder
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
KRAS Mutant Metastatic Colorectal Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Pancreatic Adenocarcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources